Myovant Sciences Ltd. (MYOV) Stock Continues Uptrend Following Pipeline Candidate Development
Myovant Sciences Ltd. (MYOV) stock prices were up by 3.33% as of the market closing on May 21st, 2021, bringing the price per share up to USD$22.98 at the end of the trading day. Launch of ORGVYX ORGOVYX saw its launch in the United States commencing in early January of the fiscal year 2021, with […]
Onconova Therapeutics, Inc. (ONTX) Stock Skyrockets Following Reverse Stock Split
Onconova Therapeutics, Inc. (ONTX) stock prices were down by a substantial 21.08% as of the market closing on May 20th, 2021, bringing the price per share down to USD$0.73 at the end of the trading day. Subsequent pre-market fluctuations saw the price skyrocket by a monumental 1235.62%, bringing the price per share up to USD$9.69. […]
Intec Pharma Ltd. (NTEC) Stock Trending Higher Following Progress on Merger with Decoy Biosystem
Intec Pharma Ltd. (NTEC) stock prices were up by 3.02% as of the market closing on May 20th, 2021, bringing the price per share up to USD$3.75 at the end of the trading day. Merger with Decoy Announced March 15th, 2021 saw NTEC announce that it had entered into a definitive agreement with Decoy Biosystems. […]
Checkpoint Therapeutics, Inc. (CKPT) Stock Undergoes Volatility after Release of Q1 2021 Financial Reports
Checkpoint Therapeutics, Inc. (CKPT) stock prices were up 4.17% as of the market closing on May 11th, 2021, bringing the price per share up to USD$2.50. Subsequent pre-market fluctuations have seen the stock fall 9.20%, down to USD$2.27. Cosibelimab Development The company recently reported the continued advancement of the development of CKPT’s two lead drug […]
Precipio, Inc. (PRPO) Stock On the Rise Following Launch of AML HemeScreen Panel
Precipio, Inc. (PRPO) stock prices were up by 15.63% as of the market closing on May 10th 2021, bringing the price per share surging to USD4.44. Subsequent pre-market fluctuations saw the stock further climb by 4.05% to hit USD$4.62. Launch of AML HemeScreen Panel PRPO recently announced the launch of its new Acute Myeloid Leukemia […]
BioLineRx Ltd. (BLRX) Stock Floats Back Down After Skyrocketing from Success of GENESIS Trial
BioLineRx Ltd. (BLRX) stock prices were down by 3.38% as of the market closing on May 7th, 2021, bringing the price per share down to USD$3.72. Subsequent pre-market fluctuations saw the price fall by another 4.30%, bringing it to USD$3.56. Phase 3 GENESIS Trial The achieving of top-line results by BLRX for their GENESIS Phase […]
Epizyme, Inc. (EPZM) Stock Experiences Volatility Following Disclosure of Q1 2021 Financial Reports
Epizyme, Inc. (EPZM) stock prices were down by 9.44% as of the market closing on May 6th 2021, bringing the price per share down to USD$6.81 at the end of the trading day. Subsequent current-market fluctuations have seen the stock rally by 20%, bringing it up to USD$8.17. Financial Reports Indicate Strong Growth The first […]
American Shared Hospital Services (AMS) Stock Continues to Soar Following Unprecedent Volumes Being Traded
American Shared Hospital Services (AMS) stock prices surged by 30.51% as of market close on May 5th, 2021, bringing the price per share up to USD$3.55. Subsequent pre-market fluctuations saw the stock further soar by 30.01%, bringing it up to USD$4.57. Revenues for Q4 2020 In the company’s most recently disclosed financial reports, AMS reported […]
Clovis Oncology, Inc. (CLVS) Stock Trending Up Following Disclosure of Promising Q1 2021 Financial Reports
Clovis Oncology, Inc. (CLVS) stock prices were up a promising 8.89% shortly after the trading day commenced on May 5th, 2021, bringing the price per share up to USD$6.00. Comparative Decrease in Revenue CLVS reported USD$38.1 million in global net product revenues derived from the company’s flagship Rubraca in the first quarter of the fiscal […]
BioLineRX Ltd (BLRX) Stock Skyrockets Following Immense Success of Phase 3 GENESIS Clinical Trial
BioLineRx Ltd. (BLRX) stock prices skyrocketed by 52.98% as of market close on May 3rd 2021, bringing the price per share up to USD$4.88 at the end of the trading day. Subsequent pre-market fluctuations have seen the stock surge another 16.6% to hit USD$5.69. Phase 3 GENESIS trial BLRX announced on May 4th, 2021 the […]
